Guilherme Sacchi de Camargo Correia, MD

Thinking about how to sequence additional agents following targeted therapy may be a key consideration in the future of lung cancer care.

Endobronchial ultrasound, robotic bronchoscopy, or other expensive procedures may exacerbate financial toxicity for patients seeking lung cancer care.

Advancements in antibody drug conjugates, bispecific therapies, and other targeted agents may hold promise in lung cancer management.